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INTRODUCTION 
Portal hypertension is a progressive complication of liver 
cirrhosis and it is the cause of high morbidity and mortality. 
Approximately 50% of patients with cirrhosis have gastroesophageal 
varices. The management of cirrhotic patients with varices differs 
according to the grade of varices or the presence of acute variceal 
bleeding. While varices are found in 40% of Child A patients, they can 
be present in up to 85% of Child C patients. Cirrhotic patients develop 
varices at a rate  8% per year and in those who have no varices at the 
time of initial endoscopic screening, and have a portal-hepatic venous 
pressure gradient (HVPG) more than 10 mmHg  is the strongest 
predictor for their development.Variceal hemorrhage occurs at a yearly 
rate 5% - 15%, and its most important predictor is the size of varices, of 
which hemorrhage with the highest risk occurring in patients with large 
varices. The gold standard for the diagnosis of varices is 
esophagogastroduodenoscopy (EGD). It is recommended that cirrhosis 
patients undergo endoscopic screening for varices at the time of 
diagnosis. Since the point prevalence of medium/large varices is 
approximately 15% - 20%, the majority of patients  undergoing 
screening EGD either do not have varices or have varices that do not 
require prophylactic therapy. Thus, several models have been proposed 
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to predict the presence of high risk varices by non-invasive methods and 
have excited considerable interest among researchers. Multiple studies 
have evaluated possible noninvasive markers of esophageal varices in 
cirrhosis patients such as: the platelet count, spleen size, Fibro test,  
diameter of  portal vein, and transient elastography. Lee and coworkers 
recently proposed a simple noninvasive test, P2/MS, which they 
developed in a study of patients with virus-related chronic liver disease 
(CLD).They used the following formula: (platelet count)2/[monocyte 
fraction (%) − segmented neutrophil fraction (%)]. However, P2/MS has 
received little external validation of its diagnostic accuracy and cut-off 
values for detection of esophageal varices. We, therefore, conducted the 
current study to externally validate P2/MS, to determine optimal 
thresholds to predict high risk esophageal varices (HREV) in patients 
with liver cirrhosis. 
The diagnosis of EV is required for patients with liver cirrhosis to 
detect those who will benefit from variceal bleeding primary 
prophylaxis. Currently, esophago-gastro-duodenoscopy (EGD) remains 
the gold standard test for such diagnosis. However, EGD is limited by 
its invasiveness and high cost. A simple non-invasive widely available 
and cheap test would be ideal if proved to have sufficient specificity and 
sensitivity. Therefore, we aimed to study the diagnostic value of an 
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index derived from the patients' complete blood count; namely the 
P2/MS ratio as a predictive tool for the presence of varices and if they 
are at high risk of bleeding. 
  
 
 
 
 
 
AIMS AND 
OBJECTIVES 
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AIMS AND OBJECTIVES 
To evaluate the predictive value of P2/MS index (platelet 
count)2/[monocyte fraction (%) × segmented neutrophil fraction (%)]  
derived from the patient's complete blood count for detecting 
oesophageal varices in cirrhosis patients presenting to Government 
Rajaji Hospital, Madurai. 
To compare the P2/MS index in cirrhosis paients with portal 
hypertension and without portal hypertension 
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REVIEW OF LITERATURE 
Cirrhosis is a pathologic entity defined as diffuse hepatic fibrosis 
with the replacement of the normal liver architecture by nodules,which 
is a final pathway for a wide variety of chronic liver diseases. The 
diagnosis of cirrhosis in clinical practice is based on risk factors, history 
and clinical findings, biochemical tests, imaging, endoscopic and 
histologic findings 
PATHOGENESIS 
The most common cell type involved in the pathogenesis of 
fibrosis is hepatic stellate cell.on activation stellate cell transforms into 
myofibroblast.these cell generate various forms of matrix of which 
fibronectin is earliest form which produce other forms of matrix 
including collagen 1.matrix deposition leads to further stellate cell 
activation and changes in the angioarchitecture. 
The canonical pathways involved are kinase activation 
pathwaysmediated through PDGF and TGF-beta and integrin signaling 
pathways.portal fibroblast is implicated in fibrosis that develop in 
response to cholestatic injury as in primary biliary cirrhosis and primary 
sclerosing cholangitis 
6 
 
Epithelial cell injury is the initiating step in liver injury and leads to 
fibrosis.macrophage release inflammatory cytokines that activate stellate 
cells into myofibroblast.sinusoidal endothelial cells also involved in the 
development of fibrosis through autocrine and paracrine signaling 
pathways. 
CAUSES OF CIRRHOSIS 
Viral 
Hepatitis B 
Hepatitis C 
Hepatitis D 
Autoimmune 
Autoimmune hepatitis 
Primary biliary cirrhosis 
Primary sclerosing cholangitis 
Toxic 
Alcohol 
Arsenic 
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Metabolic 
Alpha1antitrypsin deficiency 
Galactosemia 
Glycogen storage disease 
Hemochromatosis 
Nonalcoholic fatty liver disease 
Wilson disease 
Biliary 
Atresia 
Stone 
Tumor 
Vascular 
Budd chiari syndrome 
Cardiac fibrosis 
Genetic 
Cystic fibrosis 
Lysosomal acid lipase deficiency 
8 
 
Iatrogenic  
biliary injury 
drugs-high dose vit A,methotrexate 
CLINICAL FEATURES 
Cirrhosis can be either compensated or decompensated 
The development of ascites,jaundice,encephalopathy,variceal 
hemorrhage,hepatocellular carcinoma characterizes decompensated 
cirrhosis. 
Four clinical stages have been proposed 
Stage 1 and 2 represents compensated cirrhosis  
Stage 3 and 4 represents decompensated cirrhosis 
Stage 1-absence of both ascites and varices 
Stage 2-presence of varices without bleeding 
              Absence of ascites 
Stage 3-ascites with or without varices 
Stage 4-variceal bleeding with or without ascites 
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COMPENSATED CIRRHOSIS: 
 The cirrhotic process of the liver is not enough severe to alter the 
function significantly and so the patients may be asymptomatic or 
present only with non-specific symptoms or finding  incidentally due to 
alteration in biochemical parameters or imaging studies. Patients may be 
presented with  fatigue, anorexia, weight loss, flatulence, dyspepsia or 
abdominal pain. palmar erythema, pedal edema, spider naevi, 
unexplained epistaxis may be present. 
Abdominal examination - epigastric mass which is the enlarged 
left lobe of the liver and splenomegaly may be present. Biochemical 
tests are usually  normal   . The most common  abnormality noticed  in 
this group include mildly elevated transaminases, or GGT.cirrosis is 
confirmed by liver imaging or liver biopsy. Factors which may 
precipitate decompensation in a compensated cirrhosis are bacterial 
infection, trauma,  medications, surgery etc., 
DECOMPENSATED CIRRHOSIS: 
These patients may  present with  ascites, jaundice, altered 
sensorium,gastrointestinal bleeding . 
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SYMPTOMS AND SIGNS 
General weakness,muscle wasting,weight loss 
Mild fever(37.5-38* c)-due to gram negative bacteremia 
Jaundice-liver cell destruction exceeds the capacity for regeneration 
Skin pigmentation 
Clubbing 
Purpura –low platelet count 
Sparse body hair 
Vascular spiders 
Palmar erythema 
White nails  
Gonadal atrophy 
Ascites 
Pedal edema 
Hepatomegaly 
spleenomegaly 
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blood pressure low 
Dupuytrens contracture” 
Parotid enlargement, alopecia, fetor hepaticus, KF ring 
Gynecomastia in males 
loss of axillary hair and chest hair  
11% of cirrhosis patients have peptic ulcers -duodenal ulcers are more 
frequentiy encountered than gastric ulcers 
Asterixis or flapping tremors are present in  hepatic encephalopathy. 
In about 80% of cirrhotic patients  hyperglycemia occurs in the form of 
glucose intolerance 
INVESTIGATIONS: 
LIVER FUNCTION TEST ABNORMALITIES- 
“Aminotransferases” —ALT is increased more than AST in 
chronic hepatitis, AST becomes more elevated than ALT when  hepatitis 
progresses to cirrhosis and thus the ratio of AST to ALT is reversed 
from <1 to > 1.In cirrhosis patients the enzymes may be within normal 
values or become moderately elevated. 
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“Alkaline phosphatase” - Alkaline phosphatase enzyme  elevated 
2 to 3 times than normal in cirrhosis. If elevated greater  than that, 
primary biliary cirrhosis or sclerosing cholangitis should be considered 
as  etiology. 
“Gammaglutamyl transpeptidase” —  GGT and alkaline 
phosphatase are usually proportionately elevated.Disproportionately 
high levels of GGT are seen in alcoholic discease.GGT present in the 
rnicrosomes gets induced due to alcohol intake. 
“Bilirubin” — In compensated  cirrhosis, the bilirubin levels are 
usually normal. Decompensation - characterized by increasing levels of 
bilirubin and it is one of the prognostic indicators used in Child Pugh 
score. 
“Albumin” -  exclusively synthesised in the liver. With worsening 
cirrhosis, albumin level will be low due to the decline in the synthetic 
function of the liver.It is also one of the prognostic indicators for 
survival in child pugh scoring system. 
“Prothrombin time” -most  of the coagulation factors are 
synthesized in liver.Prothrombin time which measures the extrinsic  
pathway, is a marker for the synthetic function of the liver.  
coagulopathy worsens as the cirrhosis progresses. 
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Serum electrolytes – “hyponatremia” can occur in patients with 
ascites. Severity can be correlated with worsening cirrhosis. 
Hematologic abnormalities-Thrornbocytopenia, anemia and leucopenia 
can occur.  
“Anemia” - mainly because of upper G1 bleed. Anemia can also 
be present as a result of direct suppression of bone marrow by 
alcohol,splenic sequestration , hemolysis,and folate deficiency. 
Other abnormalities - In cirrhosis, the globulin levels- high. This 
is because of shunting of bacterial antigens in the portal venous blood 
which are normally filtered by the liver in to systemic circulation 
leading which induces production of immunoglobulins. Marked 
elevations of IgG may point towards the presence of autoimmune 
hepatitis. 
Imaging studies: 
Cirrhosis can be diagnosed radiologically by ultrasound, portal 
vein Doppler, CT and MRI in specific cases. 
• Ultrasonography — Ultrasonography is a non-invasive routinely used  
to diagnose cirrhosis. The size of the liver, the nodularity, the portal vein 
diameter,  ascites and splenomegaly can be assessed. Doppler studies to 
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check the direction of blood flow in the  portal vein aids in the diagnosis 
of portal hypertension. Presence HCC and portal vein thrombosis can 
also be made out. 
• CT is not the first choice in the diagnosis of cirrhosis, may be useful 
when investigating liver malignancy or secondaries or pancreatic 
pathology. 
• MRI- useful in hermochromatosis to reveal iron overload. MRA can 
determine portal vein flow and dynamics. 
• Elastography - assess the stiffness of the liver tissue is also available. 
Liver biopsy: 
The gold standard investigation for diagnosing cirrhosis is liver 
biopsy ,is rarely required nowadays to diagnose cirrhosis.Only certain 
situations may require performing liver biopsy such as for 
dermonstrating the underlying metabolic cause of cirrhosis such as 
NASH, Wilson disease, hemochromatosis, and alpha 1 antitrypsin 
deficiency. 
PROGNOSIS: 
Modified Child-Turcotte-Pugh Store (CTP): This simple scoring 
system is now widely in use in clinical practice, for predicting the 
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prognosis and mortality from the major complications of the cirrhosis 
patients. Even though it is not derived based on statistically significant 
studies and is only derived in an empirical manner, this score can predict 
the outcomes in patients with liver cirrhosis with reasonable accuracy. 
 
Initially this scoring system  used for the stratification of patients 
in to risk groups before taking them up for portosystermic shunt 
surgeries. Then in clinical practice this system was used to prioritize the 
patients to be taken up for liver transplantation (Child Pugh class B) but 
now this system has been replaced by MELD score for selection of 
patients for liver transplantation. 
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MODEL FOR END STAGE LIVER DISEASE (MELD) SCORE - 
MELD score is calculated using  three noninvasively obtained 
variables: serum bilirubin, serum creatinine and PT INR. 
 
Patients with cirrhosis are given priority for liver transplantation 
based on this particular score in the United States. Patient with a score 
more than 10 is to be considered for 1iver transplantation. This scoring 
system has the advantage that it is completely objective for assessment 
of severity of the disease and does not result in inter observer variations 
.Moreover the score has a wider range of values,thereby severity can be 
graded precisely. 
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MAJOR COMPLICATIONS OF CIRRHOSIS: 
With the progression of cirrhosis and development of portal 
hypertension, various complications occur as a result of either the 
decreased synthetic, excretory,metabolic functions of the liver and also 
some secondary to portal hypertension.  
COMPLICATIONS OF CIRROSIS 
Portal Hypertension 
Ascites 
Variceal bleeding 
Malignancy 
Colangiocarcinoma 
Hepatocellular carcinoma 
Bacterial infections 
Bacteremia 
c.difficile infection 
celluliis 
pneumonia 
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SBP 
UTI 
Cardiopulmonary disorder 
Cardiomyopathy 
Hepatic hydrothorax 
Hepatopulmonary syndrome 
Portopulmonary hypertension 
GI Disorders 
GI bleeding 
Protein losing enteropathy 
Venous thrombosis 
Renal disorders 
Hepatorenal syndrome 
Other causes of acute kidney injury 
Metabolic 
Adrenal insufficiency 
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Hypogonadism 
Malnutrition 
Osteoporosis 
Neuropsychiatric 
Depression 
Hepatic encephalopathy 
Hematologic 
Anemia 
Hyper coagulability 
Hypersplenism 
Impaired coagulation 
Unclear etiology  
Erectile dysfunction 
Fatigue 
Muscle cramps  
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PORTAL HYPERTENSION 
 Portal venous system carries capillary blood from the esophagus, 
stomach, small and large intestine, pancreas, gallbladder, and spleen to 
the liver. The portal vein is formed by the confluence of the splenic vein 
and the superior mesenteric vein behind the neck of the pancreas . The 
inferior mesenteric vein usually drains into the splenic vein. The left 
gastric vein, also called the left coronary vein,usually drains into the 
portal vein at the confluence of the splenic vein and superior mesenteric 
vein . The portal vein is approximately 7.5 cm in length and runs dorsal 
to the hepatic artery and bile duct into the hilum of the liver. The 
uppermost 5 cm of the portal vein does not receive any tributaries. In the 
hilum of the liver, the portal vein divides into the left and right portal 
vein branches,which supply the left and right sides of the liver, 
respectively.The umbilical vein drains into the left portal vein. 
The cystic vein from the gallbladder drains into the right portal 
vein, whereas the portal venules drain into hepatic sinusoids that, in 
turn, are drained by the hepatic veinsinto the inferior vena cava. The left 
and middle hepatic veins usually join and drain into the inferior vena 
cava separately but adjacent to the confluence of the right hepatic vein 
with the inferior vena cava. The caudate lobe drains separately into the 
inferior vena cava. 
21 
 
The circulatory system of the normal liver is a high 
compliance,low-resistance system that is able to accommodate a large 
blood volume, as occurs after a meal, without substantially increasing 
portal pressure. The liver receives a dual blood supply from the portal 
vein and the hepatic artery that constitutes nearly 30% of total cardiac 
output. Portal venous blood derived from the mesenteric venous 
circulation constitutes approximately 75% of total hepatic blood flow, 
whereas the remainder of blood to the liver is derived from the hepatic 
artery, which provides highly oxygenated blood directly from the celiac 
trunk of the aorta.Portal vein–derived and hepatic artery–derived blood 
flow converge in high-compliance, specialized vascular channels termed 
hepatic sinusoids. A dynamic and compensatory interplay occurs 
between hepatic blood flow derived from the portal vein and that from 
the hepatic artery. Specifically, when portal venous blood flow to the 
liver is diminished, as occurs in portal vein thrombosis, arterial inflow 
increases in an attempt to maintain total hepatic blood flow at a constant 
level. Similarly, after hepatic artery occlusion, portal venous inflow 
increases in a compensatory manner. This autoregulatory mechanism, 
aimed at maintaining total hepatic blood flow at a constant level, is 
termed the hepatic arterial buffer response. 
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The sinusoids are highly permeable and thus facilitate the 
transport of macromolecules to the parenchymal hepatocytes that reside 
on the extraluminal side of the endothelial cells. The hepatic sinusoids 
are highly permeable because they lack a proper basement membrane 
and because the endothelial cells that line the sinusoids contain 
fenestrae. Other unique aspects of the hepatic sinusoids are the space of 
Disse, a virtual space located extraluminal to the endothelial cell and 
adjacent to the hepatocyte, and its cellular constituents, the hepatic 
stellate cell  and the Kupffer cell. These two cell types probably play an 
important role, in concert with the endothelial cell, in regulating 
sinusoidal hemodynamics and homeostasis and may contribute to the 
sinusoidal derangements that occur in portal hypertension. In cirrhosis, 
as well as in most noncirrhotic causes of portal hypertension, portal 
hypertension results from changes in portal resistance in combination 
with changes in portal inflow. The influence of flow and resistance on 
pressure can be represented by the formula for Ohm’s law: 
_P = F × R 
in which the pressure gradient in the portal circulation (ΔP) 
is a function of portal flow (F) and resistance to flow (R). 
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Increases in portal resistance or portal flow can contribute to increased 
pressure. Portal hypertension almost always results from increases in 
both portal resistance and portal flow. 
 Portal hypertension is defined as the elevation of the hepatic venous 
pressure gradient (HVPG)>5 mmHg . 
Portal hypertension occurs as a result of two processes happening 
simultaneously: 
I) The altered architecture of the liver due to fibrosis and regenerating 
nodules, results in increased resistance to the flow of portal blood. 
2) Increased blood flow secondary to splanchnic vasodilatation. 
This portal hypertension results in variceal bleeding and ascites.  Causes 
of portal hypertension 
Prehepatic 
Portal vein thrombosis 
Splenic vein thrombosis 
Intra hepatic 
Presinusoidal 
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Idiopathic portal hypertension 
Primary biliary cirrhosis 
Sarcoidosis 
Schistosomiasis 
Sinusoidal 
Alcoholic cirrhosis 
Alcoholic hepatitis 
Cryptogenic cirrhosis 
Postnecrotic cirrhosis 
Postsinusoidal 
Sinusoidal obstruction syndrome 
Post hepatic 
Budd-Chiari syndrome 
Constrictive pericarditis 
Inferior vena caval obstruction 
Right-sided heart failure 
Severe tricuspid regurgitation 
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Clinically significant portal hypertension occurs in around 60% of 
cirrhosis patients. 
The primary complications of portal hypertension include ascites, 
bleeding varices splenomegaly, hypersplenism etc. Splenomegaly results 
from congestion due to increased portal pressure. Hypersplenism with 
development of thrombocytopenia may be the first presentation of portal 
hypertension even before ascites may develop. 
PATHOPHYSIOLOGY: 
Portal hypertension results due to increased intrahepatic resistance 
and increased portal blood flow. As there is increased hepatic resistance, 
hepatic compliance decreases. Increase in portal pressure causes small 
changes in blood flow. A normal liver can adapt to it. But it can have a 
prominent stimulatory effect on portal pressure in the cirrhotic liver. 
Due to hyperdynamic state there is an increase in portal venous inflow. 
The Collateral vessels get dilated and new vessels sprouts. There is an 
increase in flow from high pressure portal veins to low pressure 
systemic veins. This process of angiogenesis and collateral vessel 
formation can cause esophageal varices. These changes in portal flow 
and resistance are mainly originating from mechanical and vascular 
factors. 
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 MEASUREMENT OF PORTAL PRESSURE 
 Portal pressure may be measured indirectly or directly. The most 
commonly used method of measuring portal pressure is determination of 
the hepatic vein pressure gradient (HVPG), which is an indirect method. 
Measurement of splenic pulp pressure and direct measurement of the 
portal vein pressure are invasive, cumbersome, and infrequently used 
approaches. Variceal pressure also can be measured but is not routinely 
performed in clinical practice. Measurement of liver stiffness using 
ultrasound fibroelastography or magnetic resonance elastography 
(MRE) may indicate the presence of portal hypertension but cannot yet 
be used to measure portal pressure. 
HEPATIC VEIN PRESSURE GRADIENT 
The HVPG is the difference between the wedged hepatic venous 
pressure (WHVP) and free hepatic vein pressure (FHVP). The HVPG 
has been used to assess portal hypertension since its first description in 
1951, and has been validated as the best predictor for the development 
of complications of portal hypertension. 
Measurement of the HVPG requires passage of a catheter into the 
hepatic vein under radiologic guidance until the catheter can be passed 
no further, that is, until the catheter has been “wedged” in the hepatic 
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vein. The catheter can be passed into the hepatic vein through the 
femoral vein or using a transjugular venous approach. The purpose of 
wedging the catheter is to form a column of fluid that is continuous 
between the hepatic sinusoids and the catheter. 
Therefore, the measured pressure of fluid within the catheter  
reflects hepatic sinusoidal pressure. One of the drawbacks of using a 
catheter that is wedged in the hepatic vein is that the WHVP measured 
in a more fibrotic area of liver may be higher than the pressure measured 
in a less fibrotic area because of regional variation in the degree of 
fibrosis. 
Using a balloon-occluding catheter in the right hepatic vein to 
create a stagnant column of fluid in continuity with the hepatic sinusoids 
eliminates this variation in measurement of WHVP because the balloon 
catheter measures the WHVP averaged over a wide segment of the liver. 
HVPG is not effective for detecting presinusoidal causes of portal 
hypertension. 
For example, in portal hypertension secondary to portal vein 
thrombosis, the HVPG is normal. Moreover, the HVPG may 
underestimate sinusoidal pressure in 
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primary biliary cirrhosis and other presinusoidal causes of portal 
hypertension .Therefore, HVPG is accurate for detecting only sinusoidal 
and postsinusoidal causes of portal hypertension. 
The HVPG represents the gradient between the pressure in the 
portal vein and the intra-abdominal inferior vena caval pressure. An 
elevation in intra-abdominal pressure increases both WHVP and FHVP 
equally, so that the HVPG is unchanged. The advantage of the HVPG is 
that variations in the “zero” reference point have no impact on the 
HVPG.The HVPG is measured at least three times to demonstrate that 
the values are reproducible. Total occlusion of the hepatic vein by the 
inflated balloon to confirm that the balloon is in a wedged position is 
demonstrated by injecting contrast into the hepatic vein. A sinusoidal 
pattern should be seen, with no collateral circulation to other hepatic 
veins. 
The contrast washes out promptly with deflation of the balloon. 
Correct positioning of the balloon also is demonstrated by a sharp 
increase in the recorded pressure on inflation of the balloon. The 
pressure then becomes steady until the balloon is deflated, when the 
pressure drops sharply. In experienced hands, measurement of the 
HVPG is highly reproducible, accurate, and safe. 
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Measurement of the HVPG has been proposed for the following 
indications: (1) to monitor portal pressure in patients taking drugs used 
to prevent variceal bleeding; 
 (2) as aprognostic marker; 
 (3) as an end-point in trials using pharmacologic agents for the 
treatment of portal hypertension; 
(4) to assess the risk of hepatic resection in patients with 
cirrhosis; and 
 (5) to delineate the cause of portal hypertension(i.e., presinusoidal, 
sinusoidal, or postsinusoidal) usually in combination with venography, 
right-sided heart pressure measurements, and transjugular liver biopsy. 
Although the indication for HVPG measurement with the most potential 
for widespread use is monitoring the efficacy of therapies to reduce 
portal pressure, HVPG monitoring is not done routinely in clinical 
practice because no controlled trials have yet demonstrated its 
usefulness. 
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SPLENIC PULP PRESSURE 
Determination of splenic pulp pressure is an indirect method of 
measuring portal pressure and involves puncture of the splenic pulp with 
a needle catheter. Splenic pulp pressure is elevated in presinusoidal 
portal hypertension, when the HVPG is normal. Because of the potential 
risk of complications, especially bleeding, associated with splenic 
puncture, however, the procedure is rarely used. 
PORTAL VEIN PRESSURE 
Direct measurement of the pressure in the portal vein is a rarely 
used method that can be carried out through a percutaneous transhepatic 
route, transvenous approach, or, rarely, intraoperatively (although 
anesthesia can affect portal pressure). The transhepatic route requires 
portal vein puncture performed under ultrasound guidance. A catheter is 
then threaded over a guidewire into the main portal vein.With increasing 
use of the transjugular intrahepatic portosystemic shunt (TIPS) , 
radiologists have gained expertise in puncturing the portal vein and 
measuring  portal vein pressure by a transjugular route. Direct portal 
pressure measurements are carried out when HVPG cannot be measured, 
as in patients with occluded hepatic veins caused by the Budd-Chiari 
syndrome, in whom a surgical portosystemic shunt is being 
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contemplated, or in patients with intrahepatic, presinusoidal causes of 
portal hypertension, such as idiopathic portal hypertension, in which the  
HVPG may be normal  
 Idiopathic Portal Hypertension 
Idiopathic portal hypertension is uncommon in Western countries 
but is common in parts of Asia such as India and Japan. This disorder is 
diagnosed when the portal pressure is elevated in the absence of 
significant histologic changes in the liver or extrahepatic portal vein 
obstruction. A liver biopsy specimen from affected patients may be 
entirely normal although increased concentrations of ET-1 have been 
noted in the periportal hepatocytes, portal venules, and hepatic sinusoids 
of patients with idiopathic portal hypertension. Various terms used to 
describe idiopathic portal hypertension include hepatoportal sclerosis, 
noncirrhotic portal fibrosis, and Banti’s syndrome. Use of the term 
idiopathic portal hypertension probably is best restricted to portal 
hypertension in patients in whom no hepatic lesion is found on light 
microscopy. 
The term hepatoportal sclerosis suggests obliterative portal 
venopathy with subendothelial thickening of the intrahepatic portal 
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veins; thrombosis and recanalization of these veins may follow. Fibrosis 
of the portal tracts is prominent later in the course. 
The cause of idiopathic portal hypertension is unclear in a 
majority of patients, although chronic arsenic intoxication, exposure to 
vinyl chloride, and hypervitaminosis A have been implicated . These 
etiologic factors are present in only a minority of patients. The dominant 
clinical features of the condition are variceal bleeding and 
hypersplenism related to a markedly enlarged spleen. Liver biochemical 
test levels are usually normal, although the serum alkaline phosphatase 
level may be mildly elevated. Ascites is” “uncommon. The HVPG in 
this disorder usually is normal because the site of increased resistance is 
presinusoidal. Surgical portosystemic shunts are well tolerated in these 
patients, although hepatic encephalopathy may occur on long-term 
follow-up evaluation.  Liver transplantation is rarely required in these 
patients” 
HEPATIC ENCEPHALOPATHY 
“The term hepatic encephalopathy (HE) encompasses a wide 
array of transient and reversible neurologic and psychiatric 
manifestations usually found in patients with chronic liver disease and 
portal hypertension, but also seen in patients with acute liver failure. HE 
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develops in 50% to 70% of patients with cirrhosis, and its occurrence is 
a poor prognostic indicator, with projected one- and three-year survival 
rates of 42% and 23%, respectively, without liver transplantation.  
Symptoms may range from mild neurologic disturbances to overt coma. 
HE is often triggered by an inciting event that results in a rise in the 
serum ammonia level. The precise underlying pathophysiologic 
mechanisms are not well understood, and the mainstay of therapy is the 
elimination” “of the precipitating event and excess ammonia. Liver 
transplantation generally reverses HE.  
PATHOPHYSIOLOGY 
A number of factors, occurring alone or in combination, have 
been implicated in the development of HE. These factors may differ in 
acute and chronic liver disease and include the production of eurotoxins, 
altered permeability of the blood-brain barrier, and abnormal 
neurotransmission. 
The best-described neurotoxin involved in HE is ammonia, which 
is produced primarily in the colon, where bacteria metabolize proteins 
and other nitrogenbased products into ammonia. Enterocytes synthesize 
ammonia from glutamine. Once produced, ammonia enters the portal 
circulation and, under normal conditions, is metabolized and cleared by 
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hepatocytes. In cirrhosis and portal hypertension, reduced hepatocyte 
function and portosystemic shunting contribute to increased circulating 
ammonia levels. Arterial hyperammonemia is observed in up to 90% of 
patients with HE, although serum levels are neither sensitive nor 
specific indicators of its presence”. 
“Increased permeability of the blood-brain barrier increases the 
uptake and extraction of ammonia by the cerebellum and basal 
ganglia.Acute hyperammonemia appears to have a direct effect on brain 
edema, astrocyte swelling and the transport of neurally active 
compounds such as myoinositol, and thereby contributes to HE. Other 
alterations in HE affect neuronal membrane fluidity, central nervous 
system (CNS) neurotransmitter expression, and neurotransmitter 
receptor expression and activation. The γ-aminobutyric acid (GABA)– 
system has been the most well studied. Although CNS benzodiazepine 
levels and GABA receptor concentrations are unchanged in animal 
models of HE, increased” sensitivity of the astrocyte (peripheral-type) 
benzodiazepine receptor enhances activation of the GABA-
benzodiazepine system. This activation occurs in part through a feed-
forward system in which production of neurosteroids” 
“(allopregnanolone and tetrahydrodeoxycorticosterone) by astrocytes 
further activates the GABAA-benzodiazepine receptor system. Other 
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factors that influence CNS neurotransmission, including serotonin (5-
hydroxytryptamine, 5-HT), nitric oxide (NO), circulating opioid 
peptides, manganese, and increased oxygen free radical production, 
have also been postulated to contribute to HE. Finally, 
hyperammonemia, particularly in acute liver failure, also increases 
astrocyte glutamine production via glutamine synthetase. The rise in 
astrocyte glutamine and glutamate concentrations contributes to factors 
associated with CNS dysfunction  
CLINICAL FEATURES AND DIAGNOSIS 
HE may present as a spectrum of reversible neuropsychiatric 
symptoms and signs, ranging from mild changes in cognition to 
profound coma, in patients with acute or chronic liver disease. It is often 
precipitated by an inciting event (e.g., gastrointestinal bleeding, 
electrolyte abnormalities, infections, medications, dehydration). The 
diagnosis of HE, therefore, requires careful consideration in the 
appropriate” “clinical situation. Occasionally, HE may be the initial 
presentation of chronic liver disease. Subtle findings in HE may include 
forgetfulness, alterations in handwriting, difficulty with driving, and 
reversal of the sleep-wake cycle”. 
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“Overt findings may include asterixis, agitation, disinhibited 
behavior, seizures, and coma. Other causes of altered mental status, 
particularly hypoglycemia, hyponatremia, medication ingestion, and 
structural intracranial abnormalities resulting from coagulopathy or 
trauma, should be considered and rapidly excluded in patients suspected 
of having HE”. 
“No specific laboratory findings indicate the presence of HE 
definitively. The most commonly used test to assess a patient with 
possible HE is the blood ammonia level. An elevation in the blood 
ammonia level in a patient with cirrhosis and altered mental status 
supports a diagnosis of HE. Blood ammonia levels may be elevated in 
the absence of HE, however, because of gastrointestinal bleeding or the 
ingestion of certain medications (e.g., diuretics, alcohol, narcotics”, 
“valproic acid). In addition, blood ammonia levels may be elevated in 
the presence of HE, even in the absence of cirrhosis and portal 
hypertension, in patients with metabolic disorders that influence 
ammonia generation or metabolism,” such as urea cycle disorders  and 
disorders of proline metabolism  
Use of a tourniquet when blood is drawn and delayed processing 
and cooling of a blood sample may raise the blood ammonia level. 
Measurement of arterial ammonia offers no advantage over 
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measurement of venous ammonia levels in patients with chronic liver 
disease. In patients with acute liver failure, however, elevated arterial 
ammonia levels (150 to 200 mg/dL or higher) may be predictive of the 
presence of brain edema and herniation  Of the scoring systems used to 
grade the severity of HE, the West Haven system, based on a scale of 0 
to 4, is the most widely used in clinical practice  Although clinically 
useful, the West Haven criteria are insensitive and have led to the 
development of standardized” “psychometric tests and rapid bedside 
mental status assessments to aid in the diagnosis of HE and facilitate 
research. 
One simple paper and pencil test, the portosystemic ence 
encephalopathy syndrome test (PSET), evaluates the patient’s attention, 
concentration, fine motor skills, and orientation and has been shown to 
be highly specific for the diagnosis of HE The development of these 
tests has led to recognition of the syndrome of minimal HE, in which 
abnormalities are observed on testing but clinically recognizable 
alterations of HE are minimal or not detected. The presence of minimal 
HE is common in patients with cirrhosis, appears” “to influence the 
patient’s quality of life and driving ability, and confers an increased risk 
that overt HE will develop in the patient. Whether treatment of minimal 
HE confers any benefit is an area of active investigation. 
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A number of novel imaging and functional tests have been studied 
in the diagnosis of HE. Magnetic resonance spectroscopy (MRS) has 
been used to measure brain concentrations of choline and glutamine 
noninvasively. Magnetic resonance (MR) T1 mapping with partial 
inversion recovery” “(TAPIR) has been investigated as a means to 
measure changes in the brain quantitatively over clinically relevant 
measurement times. Whether MR-based techniques can be standardized 
and become practical diagnostic tests is uncertain. The critical flicker 
frequency test, a simple light-based test that has been used to assess 
cerebral cortex function in a number of disorders, has been shown to be 
a reliable marker of minimal HE and may become a clinically useful 
screening test”. 
TREATMENT 
“Current treatments for HE are directed primarily toward the 
elimination or correction of precipitating factors bleeding, infection, 
hypokalemia, medications, dehydration), reduction in elevated blood 
ammonia levels, and avoidance of the toxic effects of ammonia in the 
CNS. In the past, dietary protein restriction was considered an important 
component of the treatment of HE. Subsequent work, however, has 
suggested that limiting protein-calorie intake is not beneficial in patients 
with HE.Vegetable and dairy proteins are preferred to animal proteins 
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because of a more” “favorable calorie-to-nitrogen ratio. Although 
branchedchain amino acid supplementation may improve symptoms 
modestly, the benefits of such supplementation are not sufficient to 
justify its routine use.” 
“Nonabsorbable disaccharides have been the cornerstone of the 
treatment of HE. Oral lactulose or lactitol (the latter is not available in 
the United States) are metabolized by colonic bacteria to byproducts that 
appear to have beneficial effects by causing catharsis and reducing 
intestinal pH, thereby inhibiting ammonia absorption. These agents 
improve symptoms in patients with acute and chronic HE when 
compared with placebo but do not improve psychometric test 
performance or mortality. The most common” “side effects experienced 
by patients who take lactulose are abdominal cramping, flatulence, 
diarrhea, and electrolyte imbalance. Lactulose may also be administered 
per rectum (as an enema) to patients who are at increased risk of 
aspiration, although the efficacy of enema administration has not 
been evaluated. 
Oral antibiotics also have been used to treat HE, with the” ‘aim of 
modifying the intestinal flora and lowering stool pH to enhance the 
excretion of ammonia. Antibiotics are generally used as second-line 
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agents after lactulose or in patients who are intolerant of nonabsorbable 
disaccharides. Neomycin has been approved by the U.S. Food and Drug 
Administration (FDA) for use in acute HE in a dose of 1 to 3 g orally 
every six hours for up to six days but has been used more commonly 
off-label to treat chronic HE in doses of 0.5 to 1 g every 12 hours, in 
addition to lactulose. The efficacy of neomycin in acute or chronic HE, 
however, is not clearly” “established,47 and ototoxicity and 
nephrotoxicity caused by neomycin have been reported, particularly in 
patients with preexisting renal dysfunction.4 Rifaximin has been studied 
and approved by the FDA for the treatment of chronic HE on the basis 
of the results of a multicentered, randomized, controlled trial in which 
the overall clinical efficacy and rate of side effects were similar in 
patients treated with lactitol and those treated with rifaximin.48 The 
usual dose is 400 mg orally three times daily. Two systematic reviews” 
“of randomized controlled trials that compared rifaximinwith other 
therapies (nonabsorbable disaccharides and other antibiotics) for the 
treatment of acute or chronic HE have confirmed that the efficacy and 
side effect profiles are comparable. Other antibiotics, including 
metronidazole and vancomycin, have been reported to be effective in 
small trials and case series, but the data to support their use are 
insufficient. In addition to antibiotics, several other agents that may 
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modify intestinal flora and modulate ammonia generation or absorption 
have been evaluated as potential treatments for HE. Acarbose, an 
intestinal α-glucosidase inhibitor used to treat type 2 diabetes mellitus, 
inhibits the intestinal absorption of carbohydrates and glucose and 
results in their enhanced delivery to the colon. As a result, the ratio of 
saccharolytic to proteolytic bacterial flora is increased, and blood 
ammonia levels are decreased. A randomized, controlled, double-blind, 
crossover trial has demonstrated that acarbose improves mild HE in 
patients with cirrhosis and adult-onset diabetes mellitus.Similarly, 
probiotic regimens have been used to modify intestinal flora and” 
“diminish ammonia generation. Four small studies have suggested that 
these agents may be beneficial in humans with mild HE. These agents 
merit further evaluation and may be alternatives for patients who do not 
tolerate lactulose. 
Strategies to enhance ammonia clearance may also be useful in 
the treatment of HE. Sodium benzoate, sodium phenylbutyrate, and 
sodium phenylacetateall of which increase ammonia excretion in urine, 
are approved by the FDA for the treatment of hyperammonemia 
resulting from urea cycle enzyme defects and may improve HE in 
cirrhosis . Administration of sodium benzoate, however, results in a high 
sodium load, and the efficacy of this agent is not clearly established. The 
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combination of intravenous sodium phenylacetate and sodium benzoate 
(Ammonul, Ucyclyd Pharma, Scottsdale, Ariz) in HE is being studied. 
Administration of zinc, which has been used because zinc deficiency is 
common in patients with cirrhosis  and because zinc increases the 
activity of ornithine transcarbamylase, an enzyme in the urea cycle, may 
also” “improve HE; however, clear efficacy has not been established. 
Extracorporeal albumin dialysis using the molecular adsorbent 
recirculating system (MARS) has resulted in a reduction in blood 
ammonia levels and improvement in severe HE in patients with acute-
on-chronic liver failure  Further studies are needed to clarify whether 
albumin dialysis has a role in treatment of HE. Finally, l-ornithine–l-
aspartate (LOLA), a salt of the amino acids ornithine and aspartic acid 
that activates the urea cycle and enhances ammonia clearance, has been 
shown in several randomized controlled studies to improve HE 
compared with lactulose. Flumazenil is a specific benzodiazepine 
(GABAA receptor) antagonist that has been used in patients with HE. It 
improves the degree of encephalopathy and electrophysiologic findings 
in approximately one fourth of patients with grade 3 or 4 HE. It has a 
short half-life and a number of potential side effects, including seizures, 
arrhythmias, and withdrawal symptoms, that limit its clinical 
usefulness.” 
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GASTROESOPHAGEAL VARICES: 
Varices -dilated and tortous veins that  commonly develop within 
the oesophagus and stomach of patients with cirrhosis.  They are Porto-
systemic collaterals — ie.vascular channels that link the portal venous 
and the systemic venous circulation and develop as a result of portal 
hypertension, preferentially in the submucosa of the lower esophagus 
and also in stomach. 
Sites of portal collaterals:” 
1. Oesophageal and gastric varices 
2. Hemorrhoids. 
3. Caput medusae. 
4. Retroperitoneal sites 
 bleeding from esophageal varices are associated with a high 
mortality , the mortality rate still remains high (20%-35%) . bleeding 
contributes to 10–30% of all cases of UGI bleeding . 
EPIDEMIOLOGY: 
Most common location - distal oesophagus,but varices  occur in 
anywhere along the gastrointestinal tract.  50% of patients with cirrhosis 
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may develop gastroesophageal varices, Gastric varices are present in 5–
33% of patients with portal hypertension.The frequency of esophageal 
varices varies from 30% to 60% in patients with Cirrhosis and 9–38% of 
patients have “high-risk”varices. 
Annual rate of development of varices in patients with cirrhosis is 
around 5–8%, but the  risk of bleeding in only 1–2% of cases. 
PATHOPHYSIOLOGY: 
Four distinct zones of venous drainage at the gastroesophageal 
junction are particularly relevant to the formation of esophageal varices. 
The “gastric zone”, which extends for 2 to 3 cm below the 
gastroesophageal junction, comprises veins that are longitudinal and 
located in the submucosa and lamina propria. They come together at the 
upper end of the cardia of the stomach and drain into short gastric and 
left gastric veins.The “palisade zone” extends 2 to 3 cm proximal to the 
gastriczone into the lower esophagus. Veins in this zone run 
longitudinally and in parallel in 4 groups corresponding to the 
esophageal mucosal folds. These veins anastomose with “veins” in the 
lamina propria. The perforating veins in the palisade zone do not 
communicate with extrinsic (periesophageal) veins in the distal 
esophagus,hence more chance of bleeding. The palisade zone is the 
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dominant watershed area between the portal and systemic 
circulations.More proximal to the palisade zone in the esophagus is the 
“perforating zone”, where there is a network of veins. These veins are 
less likely to be longitudinal and are termed “perforating veins” because 
they connect the veins in the esophageal submucosa and the external 
veins. The “truncal zone”, the longest zone, is approximately 10 cm in 
length, located proximal to the perforating zone in the esophagus, and 
usually characterized by 4 longitudinal veins in the lamina propria and 
they are unlikely to bleed.The periesophageal veins drain into the 
azygos system, and as a result, an increase in azygos blood flow is a 
hallmark of portal hypertension. The venous drainage of the lower end 
of the esophagus is through the coronary vein, which also drains the 
cardia of the stomach, into the portal vein. 
The fundus of the stomach drains through short gastric veins into 
the splenic vein. In the presence of portal hypertension , varices may 
therefore form in the fundus of the stomach.Splenic vein thrombosis 
usually results in isolated “gastric fundal varices” 
“Because of the proximity of the splenic vein to the renal vein, 
spontaneous splenorenal shunts may develop and are more common in 
patients with gastric varices than in those with esophageal varices. 
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The development of gastroesophageal varices requires a portal 
pressure gradient of at least 10 mm Hg. Furthermore, a portal pressure 
gradient of at least 12 mm Hg is thought to be required for varices to 
bleed; other local factors that increase variceal wall tension are also 
needed because not all patients with a portal pressure gradient of greater 
than 12 mm Hg bleed. Factors that influence variceal wall tension can 
be viewed in the context of “Laplace’s law”: 
T = Pr/w 
T is variceal wall tension 
P is the transmural pressure gradient between the variceal and 
esophageal lumen 
r is the variceal radius 
w is the variceal wall thickness. 
When the variceal wall thins and the varix increases in diameter 
and pressure, the tolerated wall tension is exceeded and the varix 
ruptures. These physiologic observations are manifested clinically  by 
the observation that patients with larger varices (r) in sites of limited soft 
tissue support (w), with elevated portal pressure” “(P), tend to be at 
greatest risk for variceal rupture from variceal wall tension (T) that 
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becomes excessive. One notable site in which soft tissue support is 
limited is at the gastroesophageal  junction.. 
DIAGNOSIS OF VARICES: 
“Upper GI endoscopy” is the most commonly used method and 
also gold standard to detect varices. The consensus is that all patients 
diagnosed with cirrhosis of the liver should be screened for esophageal 
varices by endoscopy. Surveillance endoscopies are recommended on 
the basis of the level of cirrhosis and the presence and size of the varices  
Patients with Compensated cirrhosis and No varices - Every 2–3 
years  Compensated cirrhosis with small varices - Every 1–2 years 
Decompensated cirrhosis - Yearly intervals 
Wireless video capsule endoscopy, CT imaging,Doppler 
ultrasonography, radiography/barium swallow of the esophagus and 
stomach, and portal vein angiography and manometry are alternative 
screening modalities in patients who are not candidates for upper 
endoscopy”. 
“ESOPHAGEAL VARICES 
Endoscopic grading of esophageal varices is subjective.Various 
criteria have been used to try to standardize the reporting of esophageal 
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varices. The most commonly used criteria are those compiled by the 
“Japanese Research Society for Portal Hypertension . The descriptors 
include 
 
 
of the varix, and 
 
“Red color signs” include 
1) “red wale markings”, which are longitudinal whip-like marks on the 
varix 
2) “cherry-red spots”, which usually are 2 to 3 mm or less in diameter 
3) “hematocystic spots”, which are blood-filled blisters 4 mm or greater 
in diameter 
4) diffuse redness. 
The color of the varix can be white or blue. The form of the varix 
at endoscopy is described most commonly as 
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ortuous and occupying less than one third of theesophageal 
lumen (grade II)” 
“
lumen (grade III). 
Varices can be in the lower third, middle third, or upper third of 
the esophagus. Of all of the aforementioned descriptors, the size of the 
varices in the lower third of the esophagus is the most important. The 
size of the varices in the lower third of the esophagus is determined 
during withdrawal of the endoscope. Small varices are less than 5 mm in 
diameter, whereas large varices are greater than 5 mm in diameter. 
Another grading which is used in this study is the Paquet 
classification, where varix size is graded on a 4-point Likert scale: 
 
 
 
ddle of the 
lumen. 
Grade 1 and 2 are small varices and grade 3 and 4 are large 
varices.Others are two size ,three size classifications. 
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Patients with large esophageal varices, Child-Pugh class C 
cirrhosis, and red color signs on varices have the highest risk of variceal 
bleeding within 1 year “Progression from small to large varices” are 
associated with” 
• Decompensated cirrhosis  
• Alcoholic cirrhosis 
• Presence of red wale marks at baseline endoscopy  
Risk factors  for “Initial variceal bleeding”  are: 
• large varices (>5 mm) with red color signs 
• high CTP or MELD score 
• continuing alcohol consumption 
• high HVPG  >16 mm hg 
• coagulopathy 
“Variceal haemorrhage” is diagnosed on the basis of one of the 
following findings on endoscopy: 
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GASTRIC VARICES: 
There are three types of classification commonly used for GV. 
1. Sarin’s classification 
2. Hashizome classification 
3. Arakawa’s classification. 
Most commonly used classification is Sarin’s classification. 
SARIN’S CLASSIFICATION 
Gastric varices are categorized into four types based on the 
relationship with esophageal varices, as well as by their location in the 
stomach . 
a. Gastroesophageal varix (GOV) type 1: Extension of esophageal 
varices along lesser curve. 
b. Gastroesophageal varix type 2: Extension of esophageal varices along 
greater curve. 
c. isolated gastric varices type1 in stomach 
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d.isolated gastric varices type 2 in duodenum 
GV drain into the systemic vein via the esophageal 
paraesophageal varices (gastroesophageal venous system), the inferior 
phrenic vein (IPV) (gastrophrenic venous system), or both. These 
drainage types generally correspond to the classification system of Sarin 
et al. GOV1 drains via esophageal and paraesophageal varices, IGV1 
drains via the left IPV, and GOV2 drains via both esophageal varices 
and the IPV. GV form at the hepatopetal collateral pathway that 
develops secondary to  localized portal hypertension and drain via the 
gastric veins, thereby corresponding with IGV2 . 
TREATMENT : 
The treatment of portal hypertension is aimed either at reducing 
portal blood flow with pharmacologic agents, such as beta blockers or 
vasopressin and its analogs, or at decreasing intrahepatic resistance with 
pharmacologic agents, such as nitrates, or by radiologic or surgical 
creation of a portosystemic shunt.Treatment also may be directed at the 
varices with use of endoscopic or radiologic techniques. 
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PHARMACOLOGIC THERAPY: 
It consist of “splanchnic vasoconstrictors” (vasopressin and 
analogues,somatostatin  analogues, nonselective beta-blockers) and 
“venodilators” (nitrates). 
Vasoconstrictors act by producing splanchnic vasoconstriction 
and reducing portal venous inflow. Venodilators theoretically act by 
decreasing intrahepatic and/or portocollateral resistance. 
Drugs That Decrease Portal Blood Flow 
-adrenergic blocking agents 
 
 
Drugs That Decrease Intrahepatic Resistance 
-Adrenergic blocking agents (e.g., prazosin) 
 
Nitrates 
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ENDOSCOPIC THERAPIES - 
“sclerotherapy or endoscopic variceal ligation (EVL) 
SHUNTING THERAPY 
 radiological (transjugular intrahepatic portosystemic shunt) or 
surgical,  markedly reduces portal pressure by bypassing the site of 
increased resistance. 
“Vasopressin” is an endogenous peptide hormone that causes 
splanchnic vasoconstriction, reduces portal venous inflow, and reduces 
portal pressure. This drug is associated with serious systemic side 
effects. “Terlipressin” is another semisynthetic analogue with lesser side 
effects. 
“Somatostatin” is a 14–amino acid peptide. Following IV 
injection, somatostatin has a half-life in the circulation of 1 to 3 minutes; 
therefore, longer-acting analogs of somatostatin have been synthesized. 
The best known of these analogs are octreotide, lanreotide, and 
vapreotide. Somatostatin decreases portal pressure and collateral blood 
flow by inhibiting release of glucagon. Somatostatin also decreases 
portal pressure by decreasing postprandial splanchnic blood flow. 
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“Octreotide” has a half-life in the circulation of 80 to 120 minutes 
following iv administraton. Its effect on portal pressure is not 
prolonged,however. Moreover, continuous infusion of octreotide does 
not decrease portal pressure despite decreasing the postprandial increase 
in portal pressure. Long-acting octreotide does not reliably reduce portal 
pressure, and side effects with higher doses preclude use of this agent 
for the treatment of portal hypertension. Some randomized controlled 
trials support the view that somatostatin or octreotide may be equivalent 
in efficacy to terlipressin or sclerotherapy for controlling acute variceal 
bleed. In clinical practice,somatostatin or octreotide administration is 
combined with endoscopic management of variceal bleeding. 
“ Nonselective beta blockers” such as propranolol or nadolol are 
preferred. Blockade of β1-adrenergic receptors in the heart decreases 
cardiac output.Blockade of β2-adrenergic receptors, which cause 
vasodilatation in the mesenteric circulation, allows unopposed action of 
α1-adrenergic receptors and results in decreased portal flow.The 
combination of decreased cardiac output and decreased portal flow leads 
to a decrease in portal pressure. The effectiveness of beta blockers is 
assessed most accurately by monitoring the HVPG. The acute 
hemodynamic response (decrease in HVPG to < 12 mm Hg, or by 10%) 
20 minutes after administration of IV propranolol may be used to predict 
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the long-term reduction in bleeding risk. The benefit of beta blockers is 
reduced when hepatic function worsens. The usual method of 
monitoring the efficacy of beta blockers is to observe a decrease in the 
heart rate, which is a measure of β1-adrenergic receptor blockade. 
“Carvedilol” is a drug that has both nonselective β-blocker and 
weak α-receptor blockade activity. α-Receptor activity normally 
increasesresistance within the intrahepatic circulation. Therefore, 
blockade of the α-receptor decreases intrahepatic vascular resistance, 
which results in a further reduction in portal pressure Carvedilol is also 
known to have antioxidant as well as antiproliferative actions and may 
be superior to endoscopic variceal ligation in the prevention of a first 
variceal bleed .Carvedilol has been demonstrated to be equivalent to a 
combination of nadolol and isosorbide mononitrate in reducing variceal 
rebleeding, with fewer side effects.Carvedilol is started in a dose of 6.25 
mg once daily, and the dose is increased stepwise to a maximum of 25 
mg daily. Dose increases are usually limited by arterial hypotension.   
“Nitrates”- Short-acting (nitroglycerin) or long-acting (isosorbide 
mononitrate) nitrates result in vasodilatation. The vasodilatation results 
from a decrease in intracellular calcium in vascular smooth muscle cells. 
Nitrates cause venodilatation, rather than arterial dilatation, and decrease 
portal pressure predominantly by decreasing portal venous blood flow. 
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Nitroglycerin has been used in combination with vasopressin to control 
acute variceal bleeding. The rate of infusion of nitroglycerin is 50 to 400 
μg per minute, provided that the systolic blood pressure is greater than 
90 mm Hg; however, the combination of vasopressin and nitroglycerin 
is seldom used nowadays. Nitrates are no longer recommended, either 
alone or in combination with a beta blocker, for primary prophylaxis to 
prevent first variceal bleeds. For secondary prophylaxis (to prevent 
variceal rebleeding), isosorbide mononitrate may be added to a beta 
blocker if the beta blocker alone has not resulted in an appropriate 
decrease in HVPG. 
Drugs like prazosin,losartan,simvastatin may decrease 
intrahepatic resistance. 
ENDOSCOPIC THERAPY: 
Endoscopic therapy is the only treatment modality that is widely 
accepted for the prevention of variceal bleeding,control of acute variceal 
bleeding, and prevention of variceal rebleeding. Endoscopic variceal 
therapy includes variceal sclerotherapy and band ligation. 
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SCLEROTHERAPY  
Endoscopic sclerotherapy has largely been supplanted by 
endoscopic band ligation, except when poor visualization precludes 
effective band ligation of bleeding varices. The technique involves 
injection of a sclerosant into (intravariceal) or adjacent to (paravariceal) 
a varix.The sclerosants used include sodium tetradecyl sulfate,sodium 
morrhuate, ethanolamine oleate, and absolute alcohol.Complications 
include retrosternal discomfort, sclerosant-induced esophageal ulcer-
related bleeding, strictures, and perforation. 
VARICEAL LIGATION: 
Endoscopic variceal ligation is the preferred endoscopic modality 
for control of acute esophageal variceal bleeding and prevention of 
rebleeding; however, the utility of band ligation in the treatment of 
gastric varices is limited. 
Variceal ligation is simpler to perform than injection 
sclerotherapy. The procedure involves suctioning of the varix into a cap 
fitted on the tip of an endoscope and deploying a band around the 
varix.The band strangulates the varix, thereby causing thrombosis. 
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Multi-band devices can be used to apply several bands without 
requiring withdrawal and reinsertion of the endoscope .Varices at the 
gastroesophageal junction are banded initially,and then more proximal 
varices are banded in a spiral manner at intervals of approximately 2 cm; 
the endoscope is thenwithdrawn. Varices in the mid- or proximal 
esophagus do not need to be banded. 
Endoscopic variceal ligation is associated with fewer 
complications than sclerotherapy and requires fewer sessions to achieve 
variceal obliteration. Moreover,esophageal variceal ligation during an 
acute bleed is not associated with a sustained elevation in HVPG, as 
occurs with sclerotherapy.Endoscopic variceal ligation can cause local 
complications including esophageal ulcers , strictures, and 
dysmotility,less frequently than does sclerotherapy.Banding-induced 
ulcers can be large and potentially serious if gastric fundal varices are 
banded. A PPI is usually recommended after variceal 
ligation.Detachable snares and clips are generally not indicated. 
BALLOON TAMPONADE AND STENTS: 
From 10% to 15% of patients with an acute variceal bleeding are 
refractory to pharmacologic and endoscopic treatment.Balloon 
tamponade is used as a temporizing measure until TIPS can be carried 
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out. Varices are easily compressed because they are superficial and thin-
walled and the flow of blood is via submucosal vessels. The Sengstaken-
Blakemore tube is a triple-lumen tube: one tube is for aspirating gastric 
contents,the other allows inflation of a gastric balloon to 200 to 400 mL 
in volume, and the third inflates an esophageal balloon. The Minnesota 
tube is a modified Sengstaken-Blakemore tube. Inflation of a gastric 
balloon alone is preferred with any of these tubes. Balloon tamponade 
can control bleeding for up to 24 hours in approximately 80% to 90% of 
patients.The risk of pulmonary aspiration is reduced by placement of an 
endotracheal tube. If bleeding cannot be controlled after placement of 
the tube, reinflate and reposition the gastric balloon than to inflate the 
esophageal balloon.Because of the risks associated with placement of 
tamponade balloons, selfexpandable  metallic covered stents have been 
used to tamponade esophageal varices. 
These stents may be left in place for up to 2 weeks and then 
removed. 
TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC 
SHUNT: 
A “transjugular intrahepatic portosystemic shunt (TIPS)”— also 
referred to as a transjugular intrahepatic portosystemic stent shunt 
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(TIPSS)—reduces elevated portal pressure by creating a communication 
between the hepatic vein and an intrahepatic branch of the portal vein. A 
percutaneous transjugular approach is used to insert the shunt. A TIPS 
functions as a side-to-side portacaval shunt and has been used to treat 
complications of portal hypertension, mainly variceal bleeding and 
refractory   ascites, as well as Budd-Chiari syndrome,hepatic 
hydrothorax, and hepatorenal syndrome. 
“TIPS” has been used to control acute variceal bleeding and to 
prevent variceal rebleeding when pharmacologic and endoscopic 
therapies have failed, especially in patients with Child-Pugh class B or C 
cirrhosis, in whom bleeding is more likely to be refractory to therapy 
than in patients with Child-Pugh class A cirrhosis. The use of early TIPS 
(within 72 hours of control of variceal bleeding) in patients at high-risk 
of rebleeding (Child-Pugh class C, class B with active bleeding, or a 
MELD score > 18 and a transfusion requirement of > 4 units of red 
blood cells 
[RBCs]) is associated with a reduced rate of treatment failure and 
mortality, without an increased risk of hepatic encephalopathy, 
compared with continued pharmacologic and endoscopic therapy. When 
bleeding from varices cannot be controlled after 2sessions of endoscopic 
therapy within a 24-hour period, TIPS placement is the usualsalvage 
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treatment.TIPS is also used to treat bleeding from isolated gastric fundal 
varices, for both control of bleeding and prevention of rebleeding. 
Complications following the procedure are classified as procedure 
related, early (occurring within 30days),or late (after 30days) ,TIPS 
cannot be recommended as a first choice for preventing variceal 
rebleeding due to various complications; rather, it is reserved for 
patients who have failed endoscopic or pharmacologic therapy. 
 SURGICAL THERAPY: 
Surgical treatment of portal hypertension falls into 3 groups: 
-shunt procedures 
 
 
Surgical procedures (other than liver transplantation) are used as 
salvage therapy when standard management with pharmacologic and 
endoscopic therapy fails in patients with noncirrhotic causes of portal 
hypertension and in patients with Child-Pugh class A cirrhosis. Liver 
transplantation should be considered in all patients with cirrhosis and 
variceal bleeding 
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NON-SHUNT PROCEDURES : 
Non-shunt procedures include “esophageal transection” and 
“gastroesophageal devascularisation”. They are performed infrequently 
but may be required in selectedcases. 
SURGICAL SHUNTS: 
With the increasing availability of TIPS, the use of surgical shunts 
for refractory variceal bleeding has declined markedly.In children, 
surgical shunts are carried out almost exclusively for refractory bleeding 
due to noncirrhotic portal hypertension, such as congenital hepatic 
fibrosis and portal vein thrombosis. Surgical portosystemic shunts are 
categorized as selective shunts such as distal splenorenal 
Shunts(WARRENS SHUNT), partial shunts such as the side-to-side 
calibrated portacaval shunt, and total portosystemic shunts such as the 
side-to-side portacaval shunt or end-to-side portacaval shunt. 
GASTRIC VARICES TREATMENT: 
a. Endoscopic treatment modalities for gastric variceal bleeding. 
1. Gastric variceal sclerotherapy (GVS). 
2. Gastric variceal obturation (GVO) with glue. 
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3. Gastric variceal band ligation (GVL) with or without               
detachable snares. 
4. Thrombin injection (bovine or human). 
5. Combined endoscopic therapy. 
b. Endoscopic ultrasound-guided therapy. 
c. Radiologic intervention – 
“ transjugular intrahepatic portosystemic shunt (TIPS)” 
“ Balloon-Occluded Retrograde Transvenous Obliteration (BRTO)”. 
Management Recommendations: 
1)PATIENTS WITH CIRRHOSIS BUT NO VARICES: 
Bea blockes donot prevent varices 
Repeat EGD IN 3 years 
Immediate EGD If decompensation occurs 
2)PATIENTS WITH CIRRHOSIS AND SMALL VARICES, BUT 
NO HEMORRHAGE:  
Non selective beta blockers to prevent first variceal hemorrhage 
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3)PATIENTS WITH CIRRHOSIS AND MEDIUM OR LARGE 
VARICES, BUT NO HEMORRHAGE: 
High risk of hemorrhage- Non selective beta blockers or EVL 
preferred 
Not at high risk- beta blockers preferred,if non 
compliance,intolerance,or contraindication EVL recommended 
If a patient is placed on a nonselective beta-blocker, it should be 
adjusted to the maximal tolerated dose; follow-up surveillance EGD is 
unnecessary. It is a costeffective form of prophylactic therapy. It does 
not prevent development or growth from small to large varices and has 
significant side effects.Patientsreceiving a selective β-blocker 
(metoprolol, atenolol) for other reasons should switch to a nonselective 
β-blocker (propranolol, nadolol, or carvedilol). 
If a patient is treated with EVL, it should be repeated every 
1-2 weeks until obliteration with the first surveillance EGD 
performed 1-3 months after obliteration and then every 6-12 months to 
check for variceal recurrence.Nitrates (either alone or in combination 
with beta-blockers), shunt therapy, or sclerotherapy should not be used 
in the primary prophylaxis of variceal haemorrhage. 
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4) PATIENTS WITH CIRRHOSIS AND ACUTE VARICEAL 
HEMORRHAGE:  
Iv volume support,blood transfusion 
Antibiotic prophylaxis-oral norfloxacin,iv ciprofloxacin,iv 
ceftriaxone 
Pharmacological therapy-terlipressin,somatostatin(or octreotide, 
vapreotide) 
Treat varices with ligation or sclerotherapy 
In uncontrolled bleeding TIPS indicated 
In patients who bleed from gastric fundal varices,endoscopic 
variceal obturation using tissue adhesives such as cyanoacrylate is 
preferred, where available.Otherwise, EVL is an option.TIPS should be 
considered in patients in whom hemorrhage from fundal varices cannot 
be controlled or in whom bleeding recurs 
despite combined pharmacological and endoscopic therapy 
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5) PATIENTS WITH CIRRHOSIS WHO HAVE RECOVERED 
FROM ACUTE VARICEAL HEMORRHAGE: 
Secondary prophylaxis-- Non selective beta blockers plus EVL In 
pt with recurrent hemorrhage-surgical shunt in child A pt and refer to 
transplant center for evaluation 
RECOMMENDATIONS FOR FIRST-LINE MANAGEMENT OF 
CIRRHOTICPATIENTS AT EACH STAGE IN THE NATURAL 
HISTORY OF VARICES: 
No varices – repeat endoscopy in 2-3 years 
Small varices and no hemorrhage- repeat endoscopy in 1-2 years 
Medium/large varices and no hemorrhage- beta-blockers,EVL if 
not tolerated  variceal hemorrhage-vasoactive drug plus EVL 
WHY THERE IS A NEED FOR NONINVASIVE PREDICTORS 
OF ESOPHAGEAL VARICES? 
The diagnosis of EV is required for patients with liver cirrhosis to 
detect those who will benefit from variceal bleeding primary 
prophylaxis. 
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Currently, esophago-gastro-duodenoscopy (EGD) remains the 
gold standard test for such diagnosis. However, EGD is limited by its 
invasiveness and high cost. A simple non-invasive widely available and 
cheap test would be ideal if proved to have sufficient specificity and 
sensitivity. Therefore, we aimed to study the diagnostic value of an 
indexderived from the patients' complete blood count; namely the 
P2/MS ratio as a predictive tool for thepresence of varices and if they 
are at high risk of bleeding. 
  
 
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
STUDY POPULATION: 
The present study was conducted on 50 patients admitted with a 
diagnosis of cirrhosis of liver at general medicine and medical 
gastroenterology wards of Government Rajaji Hospital, Madurai during 
the period of may 2017 to august 2017 
Inclusion criteria: 
• Liver cirrhosis patients. Diagnosis of cirrhosis was based on 
clinical, biochemical and ultrasonographic findings. 
Exclusion Criteria 
Individuals presening with 
 previous variceal bleeding 
 β-blocker therapy or endoscopic treaments (band ligation or 
sclerotherapy) 
 portal vein thrombosis 
 previous surgery for portal hypertension or transjugular 
intrahepatic porto-systemic shunt stent placement 
 hepatocelluar carcinoma. 
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DATA COLLECTION: 
A previously designed proforma was used to collect the 
demographic and clinical details of the patients. All the patients 
underwent detailed clinical evaluation, appropriate investigations, 
imaging studies (ultrasound with Doppler) and upper g.i endoscopy. 
STUDY PROTOCOL 
 DESIGN OF STUDY: 
Prospective analytical study 
PERIOD OF STUDY: 
May 2017 to August 2017 
LABORATORY INVESTIGATIONS: 
Complete blood count – differential count,platelet count 
Liver function test 
Ultrasound abdomen 
Endoscopy 
STUDY METHODOLOGY: 
50 liver cirrhosis patients with no previous variceal bleeding and 
not on beta blocker prophylaxis were subjected to do complete blood 
count test. 
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P2/MS index was calculated using platelet count,monocyte 
fraction and neutrophil fraction. 
They were subjected to esophagogastroduodenoscopy for 
detecting esophageal varices. 
Sensitivity, specificity, positive predictive value,negative 
predictive value were calculated. 
COLLABORATING DEPARTMENTS: 
 Department of Medicine, Department of medical 
gastroenterology, Department of pathology, Department of Bio 
chemistry, Department of Radio diagnosis 
ETHICAL CLEARANCE:clearance obtained 
CONSENT:Individual written and informed consent obtained 
ANALYSIS:Statistical analysis 
CONFLICT OF INTEREST:Nil 
FINANCIAL SUPPORT: nil 
 
 
 
 
 
 
 
RESULTS AND 
INTERPRETATION 
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RESULTSAND OBSERVATIONS 
    Table 1.Age distribution of the study population (n -50) 
Age (in yrs) 
N 50 
Mean 49.0 
SD 10.6 
Minimum 31 
Maximum 72 
 
Age group (in yrs) No. (%) 
31 – 40 12 (24.0) 
41 – 50 18 (36.0) 
51 – 60 13 (26.0) 
>60 7 (14.0) 
Total 50 (100.0) 
Comments: 
Out of 50 patients 12 patients(24%) are in the age group 31-40,18 
patients(36%) are in the age group 41-50,13 patients(26%) are in the age 
group 51-60,7 patients (14%)are more than 60 years of age 
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Table 2. gender distribution of patients 
Gender No. (%) 
Male 36 (72.0) 
Female 14 (28.0) 
Total 50 (100.0) 
 
 COMMENTS: out of 50 patients 36 patients(72%) were male 
patients 14 patients (28%)were female patients
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Table 3.distribution of patients with portal hypertension and 
without portal hypertension 
Diagnosis No. (%) 
Cirrhosis with PHT 25 (50.0) 
Cirrhosis without PHT 25 (50.0) 
Total 50 (100.0) 
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Table 4 .OGD findings of the patients 
OGD Findings No. (%) 
Normal 22 (44.0) 
Oesophageal Varices – Grade I 9 (18.0) 
Oesophageal Varices – Grade II 12 (24.0) 
Oesophageal Varices – Grade III 7 (14.0) 
Total 50 (100.0) 
     
COMMENTS: 
 Out of 50 patients ,ogd findings were normal in 22 patients(44%) 
,grade I esophageal varices in 9 patients(18%) ,grade II varices in 12 
patients(24%) and grade III varices in 7 patients(14%) 
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Diagnosis 
 
Cirrhosis with PHT 
(n=25) 
Cirrhosis without PHT 
(n=25) 
 
Median (IQR) Median (IQR) 
P2/MS 
Index 
36.0 (27.0, 41.0) 138.0 (96.5, 160.5) 
p-value <0.001 (Significant) 
 
COMMENTS: 
In patients with portal hypertension the median p2/ms index was 
36 where as in patients without portal hypertension the median p2/ms 
index was 138 
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OGD Findings 
 
Normal 
(n=22) 
Oesophageal 
varices – Grade 
I (n=9) 
Oesophageal 
varices – 
Grade II 
(n=12) 
Oesophageal 
varices – Grade 
III (n=7) 
 
Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
P2/MS 
Index 
147.0 (122.5, 
171.0) 
42.0 (41.0, 
44.0) 
35.5 (32.2, 
38.0) 
21.0 (14.0, 
25.0) 
p-value <0.001 (Significant) 
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COMMENTS:  
Out of 50 patients ogd findings were normal in 22 patients with 
median p2/ms index of 147,grade I varices in 9 patients with median 
p2/ms index of 42,grade II varices in 12 patients with median p2/ms 
index of 35.5,and grade III varices in 7 patients with median p2/ms 
index of 21. 
 
 
 
 
 
 
 
ROC data for higher Oesophageal Varcies 
                               Area under the ROC curve 0.976                                                         p=0.001 
P2/MS 
Index 
Sensi 
tivity 
95% CI Specificity 95% CI PPV 95% CI NPV 95% CI +LR -LR 
>32.5 100.0 59.0 – 100.0 75.0 42.8 – 94.5 70.0 46.6 – 86.1 100.0 - 4.0 0.0 
>30.5 85.7 42.1 – 99.6 91.7 61.5 – 99.7 85.7 47.2 – 97.5 91.6 64.0 – 98.5 10.2 0.16 
>27.0 85.7 42.1 – 99.6 100.0 73.5 – 100.0 100.0 - 92.3 66.1 – 98.6 - 0.14 
 
 
 
 
 
DISCUSSION 
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DISCUSSION 
Our study was conducted to assess the predictive value of p2/ms 
index using complete blood count in finding the esophageal varices in 
cirrhosis patient and to find the cut off value below which the 
esophagealvarices are more likely present 
In this study of 50 patients 36 patients were male patients and 14 
patients were female 
Out of 50 patients ogd findings were normal in 22 patients with 
median p2/ms index of 147,grade I varices in 9 patients with median 
p2/ms index of 42,grade II varices in 12 patients with median p2/ms 
index of 35.5,and grade III varices in 7 patients with median p2/ms 
index of 21. 
In patients with portal hypertension the median p2/ms index was 
36 where as in patients without portal hypertension the median p2/ms 
index was 138 
Among 50 cirrhosis patients  ogd findings were normal in 22 
patients with median p2/ms index of 147 . 
In this study. above a cut-off value for P2/MS of 30.5, HREV 
could be excluded, with a negative predictive value [NPV] of 91.6%  
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The diagnosis of EV is required for patients with liver cirrhosis to 
detect those who will benefit from variceal bleeding primary 
prophylaxis. Currently, esophago-gastro-duodenoscopy (EGD) remains 
the gold standard test for such diagnosis. 
However, EGD is limited by its invasiveness andhigh cost. A 
simple non-invasive widely available and cheap test would be ideal if 
proved to have sufficient specificity and sensitivity. Therefore, we 
aimed to study the diagnostic value of an index derived from the 
patients' complete blood count; namely the P2/MS ratio as a predictive 
tool for the presence of varices and if they are at high risk of bleeding. 
Thus, various noninvasive tests based on biochemical and 
imaging studies have been proposed . This is particularly important in 
nations whose healthcare budget is low and the availability of 
endoscopic units is limited. Indeed, selective screening endoscopy 
becomes cost-effectivewith respect to universal screening endoscopy 
when non-invasive tests are sufficiently reliable to rule-in or rule-out the 
presence of esophageal varices. 
A new index, P2/MS, based on a complete blood count, is 
specifically designed to predict esophageal varices in chronic liver 
disease. We conducted validation of the P2/MS index, and can now 
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suggest optimal cut-off points to predict the presence of HREVs in 
patients with liver cirrhosis. Our study, has shown that a combination of 
simple, non-invasive serum markers could avoid performing 
unnecessary endoscopies, with only a small number of misdiagnosed 
cases. 
In the previous study conducted by M.A.amin et al in terms of the 
AUROC, P2/MS showed a high likelihood of reliably identifying 
patients with HREV [0.897], with values slightly lower than those seen 
in the other study by Beom Kyung et al . [0.941] . In predicting HREV, 
P2/MS showed a higher accuracy than all variables except for our new 
test variable. We have suggested one cut off point for detection of 
HREV, which differ slightly from those of Beom Kyung et al . who used 
two cut off values so patients may be in the zone between the two cut 
off values. Above a cut-off value for P2/MS of 28.85, HREV could be 
excluded, with a negative predictive value [NPV] of 86.3%. Based on 
this value, patients could avoid unnecessary endoscopy. These patients 
have a low risk of bleeding and periodic follow up using thisformula 
could be considered adequate. In contrast to other studies, our study 
aimed primarily to predict the presence of HREV rather than varices of 
any size, with the aim of selecting these patients for prophylactic 
endoscopic ligation. Empirical Beta blocker therapy for primary 
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prophylaxis can no longer be recommended for all cirrhotic patients 
without diagnostic endoscopy; it was not found to incur long term 
benefit. The formula P2/MS has several clinical advantages. First of all, 
one can easily calculate P2/MS at the bedside or in the outpatient clinic, 
as it does not require standardization and is free of intra-/interobserver 
variability. This make it different from other noninvasive tests that use 
ultrasonographic parameters such as portal vein velocity, portal vein  
diameter, hepatic impedance indexes, splenic impedance indexes and 
splenic diameter 
Similar results were shown by Kim et al , who studied the validity 
of P2/MS in predicting esophageal varices in 318 patients with hepatitis 
B (HBV) related cirrhosis. They found that P2/MS<11 reliably 
identified 83 patients as having HEV (94 % positive predictive value), 
while 179 patients were reliably identified as not having HEV with 
P2/MS more than 25 (94.4% negative predictive value). 
Overall, P2/MS reliably determined the likelihood of HEV in 262 
patients (82.4%) in their study. They recommended that patients with 
P2/MS<11 should be considered for appropriate prophylactic 
treatments, while those with P2/MS>25 may avoid endoscopy reliably. 
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In another study, 475 patients with HBV related cirrhosis were 
followed prospectively for 4 years. The risk of EV bleeding was 
significantly higher in subgroup 1: P2/MS ≥9 than in subgroup 2: 
P2/MS <9 (p = 0.029). A lower P2/MS was significant predictor for EV 
bleeding (p = 0.04). So authors recommended that different prophylactic 
treatments should be considered for the subgroup with a P2/MS <9 . 
The  study revealed that P2/MS had the highest area under the 
curve (AUROC) when compared to other studied noninvasive scores in 
detecting the presence of EV with significant difference (AUROC= 
0.987, 95% CI 0.940 - 0.998, p< 0.001). Kim et al.  found that in 
predicting EV, P2/MS AUROC (0.915, 95% CI 0.881–0.949) values 
were comparable to those of ASPRI (p = 0.968) and SPRI (p = 0.871), 
and better than those of API (p <0.001), APRI (p <0.001) and AAR ( p 
<0.001) 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION  
 
In patients with low p2/ms index esophageal varices are more 
likely present and it has emerged as significant predictors for the 
presence of esophageal varices in cirrhosis patient. 
P2/ms index was low in patients with portal hypertension when  
compared to patients without portal hypertension 
  
 
 
 
 
 
 
 
 
 
SUMMARY
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SUMMARY 
A cross sectional observational study was done at Government 
Rajaji Hospital, Madurai among 50 patients for assessing a  
noninvasive  Predictor p2/ms index using complete blood count that 
could predict the presence of  esophageal varices. P2/MS is a reliable 
simple non-invasive index for the detection and classification of EV in 
patients with cirrhosis 
We believe that this index may be of help to the physicians 
practicing in  areas where endoscopy  facilities are not readily available, 
in helping them to initiate appropriate primary  pharmacological 
prophylaxis in these patients. In a limited resources setting like 
ours,where financial constraints are a major  problem ,predicting the 
presence and grade of varices by non-invasive methods help to avoid 
unnecessary upper G.I endoscopies. 
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PROFORMA 
Name: 
Age / Sex: 
IP no: 
Occupation: 
Presenting complaints: 
h/o,jaundice, ascites, oliguria, pedal edema , gastrointestinal bleed, 
altered 
sensorium. 
Past History: 
h/o Jaundice, blood transfusion, tattoing, iv drug use, sexual promiscuity 
h/o CLD, DM, HT, CKD, CVD, DRUG INTAKE, THYROID 
DISORDERS,EPILEPSY,HEPATITIS. 
Personal history 
alcoholic/ non alcoholic 
smoker/ nonsmoker 
Clinical Examination: 
General Examination: 
92 
Consciousness, orientation, febrile/afebrile, Pallor, jaundice, Clubbing, 
Lymphadenopathy, pedal edema. 
Vitals: 
PR 
BP 
RR 
SpO2 
Systemic examination: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
Laboratory investigations: 
Complete blood count – differential count,platelet count 
Liver function test 
Ultrasound abdomen 
Endoscopy 
Diagnosis 
ABBREVIATIONS
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LIST OF ABBREVIATIONS 
LFT - liver function test 
AST - Aspartate aminotransferase 
ALT -  Alanine aminotransferase 
UGI - Upper Gastrointestinal 
MELD - Model for End stage Liver Disease score 
CTP - child turcotte pugh 
PT - prothrombin time 
TIPSS - Transjugular Intrahepatic Portosytemic Shunt Surgery 
BRTO - balloon retrograde transvenous obliteration 
NO - Nitric Oxide 
GV - gastric varices 
EVL - endoscopic variceal ligation 
EGD - esophago gastroduodenoscopy 
MASTER CHART 
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MASTER CHART 
S.NO NAME AGE SEX DIAGNOSIS 
PLATELET 
COUNT 
(X10^5 
CELLS  
/CU.MM) 
NEUTRO 
PHIL % 
MONO 
CYTE% 
P2  
/MS 
INDEX 
OGD FINDING 
1 SELVARAJ 51 M CIRRHOSIS WITH PHT 0.86 78 5 19 
OESOPHAGEAL VARICES- 
GRADE III 
2 CHINNAPPAN 58 M CIRRHOSIS WITH PHT 1.02 75 4 35 
OESOPHAGEAL VARICES- 
GRADE II 
3 KANNAN 54 M CIRRHOSIS 1.98 69 4 142 NORMAL STUDY 
4 RAMACHANDRAN 37 M CIRRHOSIS 2.1 71 3 207 NORMAL STUDY 
5 RAMALINGAM 41 M CIRRHOSIS WITH PHT 1.16 74 4 45 
OESOPHAGEAL VARICES- 
GRADE I 
6 RAJA 45 M CIRRHOSIS 1.86 70 4 123 NORMAL STUDY 
7 PONNATHAL 47 F CIRRHOSIS WITH PHT 0.68 74 3 21 
OESOPHAGEAL VARICES- 
GRADE III 
8 LAXMANAN 65 M CIRRHOSIS WITH PHT 1.02 72 4 36 
OESOPHAGEAL VARICES- 
GRADE II 
9 
MOHAMED 
ISMAYIL 
45 M CIRRHOSIS 1.63 66 3 134 NORMAL STUDY 
10 RADHAKRISHNAN 45 M CIRRHOSIS WITH PHT 0.98 72 4 33 
OESOPHAGEAL VARICES- 
GRADE II 
11 PARVATHAM 35 F CIRRHOSIS WITH PHT 1.08 72 4 39 
OESOPHAGEAL VARICES- 
GRADE II 
12 NATCHAMMAL 60 F CIRRHOSIS 1.35 68 2 134 PHT GASTROPATHY 
13 MANI 47 M CIRRHOSIS WITH PHT 1.24 75 5 41 
OESOPHAGEAL VARICES- 
GRADE I 
14 PRAKASH 60 M CIRRHOSIS 1.01 68 4 37 
OESOPHAGEAL VARICES- 
GRADE II 
95 
15 SOUNDARAJAN 66 M CIRRHOSIS WITH PHT 1.43 69 2 148 NORMAL STUDY 
16 MANORANJITHAM 62 F CIRRHOSIS 1.78 72 3 146 NORMAL STUDY 
17 PANDIYAN 40 M CIRRHOSIS 1.37 68 2 138 NORMAL STUDY 
18 PORKODI 50 F CIRRHOSIS WITH PHT 1.04 71 4 38 
OESOPHAGEAL VARICES- 
GRADE II 
19 MADHAVAN 31 M CIRRHOSIS 1.5 72 2 156 NORMAL STUDY 
20 GEETHA 36 F CIRRHOSIS 1.25 76 5 41 
OESOPHAGEAL VARICES- 
GRADE I 
21 PANDIYAMMAL 43 F CIRRHOSIS WITH PHT 0.83 71 3 32 
OESOPHAGEAL VARICES- 
GRADE III 
22 ILAYAPERUMAL 60 M CIRRHOSIS WITH PHT 0.97 68 3 46 
OESOPHAGEAL VARICES- 
GRADE I 
23 SUNDARAM 48 M CIRRHOSIS 1.48 71 2 154 NORMAL STUDY 
24 MUTHULAKSHMI 40 F CIRRHOSIS 1.82 68 3 162 NORMAL STUDY 
25 PETCHIYAMMAL 43 F CIRRHOSIS WITH PHT 0.54 68 2 21 
OESOPHAGEAL VARICES- 
GRADE III 
26 PANDI 55 M CIRRHOSIS 1.23 72 5 42 
OESOPHAGEAL VARICES- 
GRADE I 
27 DESIKAN 72 M CIRRHOSIS WITH PHT 0.92 74 3 38 
OESOPHAGEAL VARICES- 
GRADE II 
28 KRISHNAN 50 M CIRRHOSIS 2.1 69 4 159 
ESOPHAGEAL 
CANDIDIASIS 
29 BUVANEESWARI 57 F CIRRHOSIS WITH PHT 0.73 71 3 25 
OESOPHAGEAL VARICES- 
GRADE III 
30 RAVICHANDRAN 47 M CIRRHOSIS 1.67 68 2 205 NORMAL STUDY 
31 MAHESH 31 M CIRRHOSIS WITH PHT 1.16 69 2 97 NORMAL STUDY 
32 JEYARAJ 70 M CIRRHOSIS 1.13 74 4 43 
OESOPHAGEAL VARICES- 
GRADE I 
33 MUTHUVELLAI 65 M CIRRHOSIS WITH PHT 0.82 71 3 32 
OESOPHAGEAL VARICES- 
GRADE II 
34 KRISHNASAMY 57 M CIRRHOSIS WITH PHT 0.94 69 3 43 
OESOPHAGEAL VARICES- 
GRADE I 
96 
35 KOWSALYA 32 F CIRRHOSIS 1.54 65 3 121 NORMAL STUDY 
36 ASAIPANDI 45 M CIRRHOSIS 2.2 70 3 230 NORMAL STUDY 
37 DHANAM 65 F CIRRHOSIS WITH PHT 0.78 71 3 29 
OESOPHAGEAL VARICES- 
GRADE II 
38 ESWARAN 42 M CIRRHOSIS WITH PHT 0.91 70 2 39 
OESOPHAGEAL VARICES- 
GRADE I 
39 RAMASAMY 55 M CIRRHOSIS 1.18 69 2 101 NORMAL STUDY 
40 BALASUBRAMANI 37 M CIRRHOSIS WITH PHT 0.73 70 2 38 
OESOPHAGEAL VARICES- 
GRADE II 
41 SURESH 37 M CIRRHOSIS 1.26 67 2 118 NORMAL STUDY 
42 RAJENDRAN 52 M CIRRHOSIS WITH PHT 1.08 71 4 41 
OESOPHAGEAL VARICES- 
GRADE I 
43 RAVI 40 M CIRRHOSIS 1.88 69 2 256 NORMAL STUDY 
44 MURUGESAN 56 M CIRRHOSIS 1.38 69 3 92 NORMAL STUDY 
45 ABDUL KAREEM 42 M CIRRHOSIS WITH PHT 0.97 74 4 32 
OESOPHAGEAL VARICES- 
GRADE II 
46 SUSEELA 60 F CIRRHOSIS WITH PHT 0.45 70 2 14 
OESOPHAGEAL VARICES- 
GRADE III 
47 CHELLAPANDI 48 M CIRRHOSIS 1.42 68 2 148 NORMAL STUDY 
48 MEENA 35 F CIRRHOSIS 1.13 78 5 33 
OESOPHAGEAL VARICES- 
GRADE II 
49 MURUGAN 42 M CIRRHOSIS WITH PHT 0.53 70 3 13 
OESOPHAGEAL VARICES- 
GRADE III 
50 RAJKUMAR 50 M CIRRHOSIS 2.6 68 5 198 NORMAL STUDY 
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